Abaxis Inc (ABAX) 44.23 $ABAX
VCA Inc. and Abaxis, Inc. Announce Long-Term Product Supply Agreement and a Co-Marketing Agreement for Laboratory Services, VetScan Chemistry Analyzers and Reagent Discs
Business Wire - Mon May 12, 5:34PM CDT
VCA Inc. (Nasdaq: WOOF), a leading animal healthcare company in the United States and Canada, and Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today jointly announced they have entered into two long-term agreements, the first a long-term product supply agreement for VCA's Animal Hospitals and the second a co-marketing agreement with VCA's Antech Diagnostic reference laboratories.
Abaxis, Inc. and VCA Inc. Announce Long-Term Product Supply Agreement and a Co-Marketing Agreement for Laboratory Services, VetScan Chemistry Analyzers and Reagent Discs
PR Newswire - Mon May 12, 5:30PM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, and VCA Inc. (NasdaqGS: WOOF), a leading animal healthcare company in the United States and Canada, today jointly announced they have entered into two long-term agreements, the first a long-term product supply agreement for VCA's Animal Hospitals and the second a co-marketing agreement with VCA's Antech Diagnostic reference laboratories.
Global Veterinary Diagnostics Market by Products & by Animals to 2018: IDEXX Laboratories & VCA Antech Account for 45-50% Market Share
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rpb5hm/veterinary) has announced the addition of the "Veterinary Diagnostics Market by Products & by Animals - Global Forecast to 2018" report to their offering. The global veterinary diagnostics market is expected to grow at a healthy CAGR during the forecast period of 2013 to 2018 and is estimated to be worth $4,200 million by 2018. The major players in the veterinary diagnostics market include IDEXX Laboratories (U.S.), VCA Antech Inc. (U.S.), Abaxis Corporation (U.S.), Heska Corporation (U.S.), Zoetis Inc. (U.S.), Mindray Medical (China), Neogen Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.). Collectively, the top eight players accounted for nearly 75% of the global veterinary diagnostics market in 2012. IDEXX Laboratories (U.S.) and VCA Antech (U.S.) are the leading players, together accounting for around 45%-50% share in the global veterinary diagnostics market in 2012. IDEXX Laboratories has a diversified product portfolio, which includes a wide range of companion animal diagnostics products and livestock and poultry diagnostic products. The company has a strong presence in over 100 countries through its strong manufacturing and distribution facilities, which enables it to cater to a large customer base across the globe. It focuses on strengthening and streamlining its product portfolio for the veterinary diagnostics industry. Over the years, the veterinary diagnostics market has grown multi-fold, adapting various technologies from the human diagnostics segment. In the past decade, a number of new products have been launched in this market, which had a positive impact on the growth of this market. In this report, the global veterinary diagnostics market is segmented by products, type of animals, end-users, and geography. The veterinary diagnostics market is mainly classified by product into clinical chemistry, hematology analyzers, molecular diagnostics, immunodiagnostics, diagnostic imaging, and others. The animal market covers companion animals and food-producing animals. The report also discusses the key market drivers, restraints, and opportunities of the global veterinary diagnostics market and its sub-markets. The market is mainly driven by the increasing incidences of disease outbreaks, increasing companion animal market backed by the rise in the adoption of pets, increase in the disposable incomes, and the increasing incidences of zoonotic diseases. However, economic downturn and increasing adoption of vegetarian food inhibits the growth of the market to a certain extent. During the forecast period the clinical chemistry segment will continue to drive and dominate the veterinary diagnostics market. A majority share of this growth can be attributed to widening applications of various clinical assays in veterinary diagnostics industry. Furthermore, rising demand for clinical diagnostics tests for food-producing animals are also expected to drive the growth of the veterinary diagnostics market. Highly organized dairy sector, increased awareness towards prevention of diseases in livestock animals in order to meet the increased demand for meat and dairy products, and increasing number of farm animals is expected to fuel the demand for diagnostic tests during the forecast period of 2013-2018. Scope Products - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Animals - Companion - Food-producing - Dog - Livestock - Poultry - Swine Companies Mentioned - Abaxis, Inc. - Heska Corporation - Idexx Laboratories, Inc. - Idvet - Mindray Medical International Ltd. - Neogen Corporation - Thermo Fisher Scientific Inc. - Vca Antech, Inc. - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/rpb5hm/veterinary
Research and Markets: Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays
Business Wire - Wed May 07, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mcdlgw/rapid_medical) has announced the addition of the "Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays" report to their offering.
Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays
M2 - Wed May 07, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lkpprc/rapid_medical) has announced the addition of the "Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays" report to their offering. Some of the major players contributing to this market include Abbott Laboratories, Abaxis, Inc., Alere, Inc., Becton Dickinson & Company, BioRad Laboratories, F. Hoffmann La Roche, MegaCor, Trinity Biotech, Zoetis, Inc. Rapid medical diagnostics are tools for detection of various infectious diseases caused by virus and bacteria. Since the last decade remarkable prevalence of infectious diseases has been observed worldwide and its morbidity rate is rapidly growing. Increased detection of new pathogens-causing infections and increasing rate of weak immune system resulting from aging of population worldwide are some of the major factors leading to increase in the infectious diseases due to which the rapid medical diagnostic kits market is showing massive growth globally. Some other factors contributing to the growth of the rapid medical diagnostic kits market include cheaper cost of the rapid medical diagnostic kits, and increasing awareness about the available technologies for diagnosis of the infectious diseases caused by virus and bacteria. Rapid medical diagnostic kits market is mainly categorized on the basis of applications namely, clinical testing, home-use, infectious disease and veterinary and on the basis of technology used to develop rapid medical diagnostic platform namely, lateral flow technology, agglutination assays, flow-through and solid phase assays. The home-use rapid medical diagnostic application segment held the major market share of rapid medical diagnostic kits market in 2012 on account of the highly dominated blood glucose testing market. While on the technology side, lateral flow technology led the technology segment in the global rapid medical diagnostic kits market owing to presence of large number of approved rapid medical diagnostic kits with this technology. Moreover, its ease of use and quick turnaround time has been beneficial in malaria and pregnancy testing at home. The global rapid medical diagnostic kits market is highly fragmented in nature with many companies competing in the market. Well established market players dominate this market with their proprietary products and predatory growth strategies. Patent repository of the established market players is restraining growth and entry of the new market players entering into the market. Companies such as Millipore Corporation and Alere, Inc. are seeking patent approvals to secure their market share in the rapid medical diagnostic kits market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Rapid Medical Diagnostic Kits Market Overview Chapter 4 Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Chapter 5 Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Chapter 6 Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Chapter 7 Recommendations Chapter 8 Competitive Landscape Chapter 9 Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/lk...id_medical
Insider Trading Alert - MXIM, CCE And ABAX Traded By Insiders
at The Street - Mon May 05, 10:00AM CDT
Stocks with insider trader activity include MXIM, CCE and ABAX
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Mon May 05, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 11:20 a.m. PT. The conference will be held at the Encore at the Wynn in Las Vegas, NV.
Abaxis' Fiscal Q4 Earnings, Revs Disappoint Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:50AM CDT
Abaxis, Inc. (ABAX) delivers disappointing fourth-quarter and fiscal 2014 financial results
Abaxis Executive Promotions
PR Newswire - Mon Apr 28, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced organizational changes to its leadership structure.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2014; Declares Quarterly Cash Dividend
PR Newswire - Thu Apr 24, 3:00PM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fourth quarter and fiscal year ended March 31, 2014.
Federal Court Grants Preliminary Approval Of Settlement In Abaxis Shareholder Lawsuit
PR Newswire - Fri Apr 18, 3:00PM CDT
On April 15, 2014, the United States District Court for the Northern District of California, granted preliminary approval of a settlement that Abaxis, Inc. has reached with Plaintiff St. Louis Police Retirement System ("Plaintiff"
in a shareholder class and derivative action that Plaintiff filed on October 1, 2012 on behalf of itself and all others similarly situated, and derivatively on behalf of Abaxis ("Abaxis" or the "Company" , and against certain of Abaxis's officers and directors (the "Defendants" , entitled St. Louis Police Retirement System v. Severson, et al., Case No. 12-cv-05086-YGR (N.D. Cal.) (the "Action" . The Court's order granting preliminary approval of the settlement requires Abaxis to provide notice to its stockholders of the information about the Action contained in this press release.
Abaxis To Report Fourth Quarter And Fiscal Year 2014 Financial Results Thursday, April 24, 2014
PR Newswire - Tue Apr 15, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2014, ended March 31, 2014. The call will be at 4:15 p.m. ET on Thursday, April 24, 2014. The Company will report financial results for the fourth quarter and fiscal year 2014 after the market closes on Thursday, April 24, 2014.
Abaxis' Piccolo Xpress Gets Health Canada Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 2:30PM CDT
Abaxis' Piccolo Xpress gets Class III approval from Health Canada.
Abaxis receives Health Canada Class III approval for Piccolo Xpress
M2 - Wed Apr 09, 5:35AM CDT
US-based medical products company Abaxis (NasdaqGS:ABAX) reported on Tuesday the receipt of Health Canada's approval for the Piccolo Xpress and Piccolo Reagent Discs as a Class III medical devices for use throughout Canada.
Abaxis Receives Health Canada Class III Approval for Piccolo Xpress®
PR Newswire - Tue Apr 08, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced Health Canada approved the Piccolo Xpress® and Piccolo Reagent Discs as a Class III medical device for use throughout Canada. With this reclassification, Canadian healthcare providers and patients can now enjoy the benefits of lab-accurate blood chemistry diagnostics at the point-of-care.
Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018
M2 - Fri Apr 04, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cd9kt8/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018" report to their offering. The global point-of-care diagnostics market is dominated by North America, followed by Europe, Asia-Pacific and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period, followed by the Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR of -13.6% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as the huge patient population base, increasing funding/investment toward the development of point of care diagnosticproducts, growing focus of both international and domestic players on the Asia-Pacific point-of-care diagnostics market, and large number of R&D activities are driving the growth of the market in the Asia-Pacific region. A number of factors such as the rising prevalence of lifestyle and infectious diseases, increasing usage of home-based POC devices, and decreasing number of technicians in central labs are driving the growth of the global market. Furthermore, growing government support and increasing private investments and venture funding to support new product development are other factors that are propelling the growth of the market. In addition, rising adoption of POC devices, expansion of therapeutic horizon, and technological advancements is further fueling the growth of this market. However, a few pivotal factors such as lack of alignment with definitive central lab methods, and reluctance to change existing treatment practices are hindering the growth of this market. Moreover, disadvantages of POC testing over central lab methods and recalls of leading glucose monitoring devices are the foremost challenges faced by industry players. New product launches is the key strategy followed by leading market players to ensure their growth in the POC diagnostics market. Moreover, partnerships, agreements, collaboration, and joint ventures; mergers and acquisitions; and expansions are some other growth strategies adopted by industry players in the global market. Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Trends - Point-Of-Care Diagnostics Market, By Product - Point-Of-Care Diagnostics Market, By Prescription Mode - Point-Of-Care Diagnostics Market, By End User - Point-Of-Care Diagnostics Market, By Geography - Competitive Landscape - Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare Visit http://www.researchandmarkets.com/research/cd...ointofcare
CLIA Waiver for Abaxis' Lipid Profile Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 2:20PM CDT
Abaxis received the CLIA waiver status for capillary draw for cholesterol, high density cholesterol and triglycerides.
Abaxis Receives CLIA Waiver For Capillary Sampling For Cholesterol, HDL And Triglycerides
PR Newswire - Fri Mar 28, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced the Food and Drug Administration granted CLIA waived status for capillary draw for CHOL, HDL and TRIG. Combined with existing CLIA waived tests for liver diagnostics using capillary samples, Abaxis now has two complete Lipid Panels which can be used by healthcare professionals to diagnose, treat and monitor hyperlipidemia patients using a sample obtained from either venous blood or a capillary draw.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
VCA Inc. and Abaxis, Inc. Announce Long-Term Product Supply Agreement and a Co-Marketing Agreement for Laboratory Services, VetScan Chemistry Analyzers and Reagent Discs
Business Wire - Mon May 12, 5:34PM CDT
VCA Inc. (Nasdaq: WOOF), a leading animal healthcare company in the United States and Canada, and Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today jointly announced they have entered into two long-term agreements, the first a long-term product supply agreement for VCA's Animal Hospitals and the second a co-marketing agreement with VCA's Antech Diagnostic reference laboratories.
Abaxis, Inc. and VCA Inc. Announce Long-Term Product Supply Agreement and a Co-Marketing Agreement for Laboratory Services, VetScan Chemistry Analyzers and Reagent Discs
PR Newswire - Mon May 12, 5:30PM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, and VCA Inc. (NasdaqGS: WOOF), a leading animal healthcare company in the United States and Canada, today jointly announced they have entered into two long-term agreements, the first a long-term product supply agreement for VCA's Animal Hospitals and the second a co-marketing agreement with VCA's Antech Diagnostic reference laboratories.
Global Veterinary Diagnostics Market by Products & by Animals to 2018: IDEXX Laboratories & VCA Antech Account for 45-50% Market Share
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rpb5hm/veterinary) has announced the addition of the "Veterinary Diagnostics Market by Products & by Animals - Global Forecast to 2018" report to their offering. The global veterinary diagnostics market is expected to grow at a healthy CAGR during the forecast period of 2013 to 2018 and is estimated to be worth $4,200 million by 2018. The major players in the veterinary diagnostics market include IDEXX Laboratories (U.S.), VCA Antech Inc. (U.S.), Abaxis Corporation (U.S.), Heska Corporation (U.S.), Zoetis Inc. (U.S.), Mindray Medical (China), Neogen Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.). Collectively, the top eight players accounted for nearly 75% of the global veterinary diagnostics market in 2012. IDEXX Laboratories (U.S.) and VCA Antech (U.S.) are the leading players, together accounting for around 45%-50% share in the global veterinary diagnostics market in 2012. IDEXX Laboratories has a diversified product portfolio, which includes a wide range of companion animal diagnostics products and livestock and poultry diagnostic products. The company has a strong presence in over 100 countries through its strong manufacturing and distribution facilities, which enables it to cater to a large customer base across the globe. It focuses on strengthening and streamlining its product portfolio for the veterinary diagnostics industry. Over the years, the veterinary diagnostics market has grown multi-fold, adapting various technologies from the human diagnostics segment. In the past decade, a number of new products have been launched in this market, which had a positive impact on the growth of this market. In this report, the global veterinary diagnostics market is segmented by products, type of animals, end-users, and geography. The veterinary diagnostics market is mainly classified by product into clinical chemistry, hematology analyzers, molecular diagnostics, immunodiagnostics, diagnostic imaging, and others. The animal market covers companion animals and food-producing animals. The report also discusses the key market drivers, restraints, and opportunities of the global veterinary diagnostics market and its sub-markets. The market is mainly driven by the increasing incidences of disease outbreaks, increasing companion animal market backed by the rise in the adoption of pets, increase in the disposable incomes, and the increasing incidences of zoonotic diseases. However, economic downturn and increasing adoption of vegetarian food inhibits the growth of the market to a certain extent. During the forecast period the clinical chemistry segment will continue to drive and dominate the veterinary diagnostics market. A majority share of this growth can be attributed to widening applications of various clinical assays in veterinary diagnostics industry. Furthermore, rising demand for clinical diagnostics tests for food-producing animals are also expected to drive the growth of the veterinary diagnostics market. Highly organized dairy sector, increased awareness towards prevention of diseases in livestock animals in order to meet the increased demand for meat and dairy products, and increasing number of farm animals is expected to fuel the demand for diagnostic tests during the forecast period of 2013-2018. Scope Products - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Animals - Companion - Food-producing - Dog - Livestock - Poultry - Swine Companies Mentioned - Abaxis, Inc. - Heska Corporation - Idexx Laboratories, Inc. - Idvet - Mindray Medical International Ltd. - Neogen Corporation - Thermo Fisher Scientific Inc. - Vca Antech, Inc. - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/rpb5hm/veterinary
Research and Markets: Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays
Business Wire - Wed May 07, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mcdlgw/rapid_medical) has announced the addition of the "Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays" report to their offering.
Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays
M2 - Wed May 07, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lkpprc/rapid_medical) has announced the addition of the "Global Rapid Medical Diagnostic Kits Trends and Forecasts, 2013 - 2019: Lateral Flow Technology, Agglutination Assays, Flow-through and Solid-phase Assays" report to their offering. Some of the major players contributing to this market include Abbott Laboratories, Abaxis, Inc., Alere, Inc., Becton Dickinson & Company, BioRad Laboratories, F. Hoffmann La Roche, MegaCor, Trinity Biotech, Zoetis, Inc. Rapid medical diagnostics are tools for detection of various infectious diseases caused by virus and bacteria. Since the last decade remarkable prevalence of infectious diseases has been observed worldwide and its morbidity rate is rapidly growing. Increased detection of new pathogens-causing infections and increasing rate of weak immune system resulting from aging of population worldwide are some of the major factors leading to increase in the infectious diseases due to which the rapid medical diagnostic kits market is showing massive growth globally. Some other factors contributing to the growth of the rapid medical diagnostic kits market include cheaper cost of the rapid medical diagnostic kits, and increasing awareness about the available technologies for diagnosis of the infectious diseases caused by virus and bacteria. Rapid medical diagnostic kits market is mainly categorized on the basis of applications namely, clinical testing, home-use, infectious disease and veterinary and on the basis of technology used to develop rapid medical diagnostic platform namely, lateral flow technology, agglutination assays, flow-through and solid phase assays. The home-use rapid medical diagnostic application segment held the major market share of rapid medical diagnostic kits market in 2012 on account of the highly dominated blood glucose testing market. While on the technology side, lateral flow technology led the technology segment in the global rapid medical diagnostic kits market owing to presence of large number of approved rapid medical diagnostic kits with this technology. Moreover, its ease of use and quick turnaround time has been beneficial in malaria and pregnancy testing at home. The global rapid medical diagnostic kits market is highly fragmented in nature with many companies competing in the market. Well established market players dominate this market with their proprietary products and predatory growth strategies. Patent repository of the established market players is restraining growth and entry of the new market players entering into the market. Companies such as Millipore Corporation and Alere, Inc. are seeking patent approvals to secure their market share in the rapid medical diagnostic kits market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Rapid Medical Diagnostic Kits Market Overview Chapter 4 Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Chapter 5 Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Chapter 6 Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Chapter 7 Recommendations Chapter 8 Competitive Landscape Chapter 9 Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/lk...id_medical
Insider Trading Alert - MXIM, CCE And ABAX Traded By Insiders
at The Street - Mon May 05, 10:00AM CDT
Stocks with insider trader activity include MXIM, CCE and ABAX
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Mon May 05, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 11:20 a.m. PT. The conference will be held at the Encore at the Wynn in Las Vegas, NV.
Abaxis' Fiscal Q4 Earnings, Revs Disappoint Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:50AM CDT
Abaxis, Inc. (ABAX) delivers disappointing fourth-quarter and fiscal 2014 financial results
Abaxis Executive Promotions
PR Newswire - Mon Apr 28, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced organizational changes to its leadership structure.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2014; Declares Quarterly Cash Dividend
PR Newswire - Thu Apr 24, 3:00PM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fourth quarter and fiscal year ended March 31, 2014.
Federal Court Grants Preliminary Approval Of Settlement In Abaxis Shareholder Lawsuit
PR Newswire - Fri Apr 18, 3:00PM CDT
On April 15, 2014, the United States District Court for the Northern District of California, granted preliminary approval of a settlement that Abaxis, Inc. has reached with Plaintiff St. Louis Police Retirement System ("Plaintiff"
in a shareholder class and derivative action that Plaintiff filed on October 1, 2012 on behalf of itself and all others similarly situated, and derivatively on behalf of Abaxis ("Abaxis" or the "Company" , and against certain of Abaxis's officers and directors (the "Defendants" , entitled St. Louis Police Retirement System v. Severson, et al., Case No. 12-cv-05086-YGR (N.D. Cal.) (the "Action" . The Court's order granting preliminary approval of the settlement requires Abaxis to provide notice to its stockholders of the information about the Action contained in this press release. Abaxis To Report Fourth Quarter And Fiscal Year 2014 Financial Results Thursday, April 24, 2014
PR Newswire - Tue Apr 15, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2014, ended March 31, 2014. The call will be at 4:15 p.m. ET on Thursday, April 24, 2014. The Company will report financial results for the fourth quarter and fiscal year 2014 after the market closes on Thursday, April 24, 2014.
Abaxis' Piccolo Xpress Gets Health Canada Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 2:30PM CDT
Abaxis' Piccolo Xpress gets Class III approval from Health Canada.
Abaxis receives Health Canada Class III approval for Piccolo Xpress
M2 - Wed Apr 09, 5:35AM CDT
US-based medical products company Abaxis (NasdaqGS:ABAX) reported on Tuesday the receipt of Health Canada's approval for the Piccolo Xpress and Piccolo Reagent Discs as a Class III medical devices for use throughout Canada.
Abaxis Receives Health Canada Class III Approval for Piccolo Xpress®
PR Newswire - Tue Apr 08, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced Health Canada approved the Piccolo Xpress® and Piccolo Reagent Discs as a Class III medical device for use throughout Canada. With this reclassification, Canadian healthcare providers and patients can now enjoy the benefits of lab-accurate blood chemistry diagnostics at the point-of-care.
Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018
M2 - Fri Apr 04, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cd9kt8/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018" report to their offering. The global point-of-care diagnostics market is dominated by North America, followed by Europe, Asia-Pacific and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period, followed by the Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR of -13.6% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as the huge patient population base, increasing funding/investment toward the development of point of care diagnosticproducts, growing focus of both international and domestic players on the Asia-Pacific point-of-care diagnostics market, and large number of R&D activities are driving the growth of the market in the Asia-Pacific region. A number of factors such as the rising prevalence of lifestyle and infectious diseases, increasing usage of home-based POC devices, and decreasing number of technicians in central labs are driving the growth of the global market. Furthermore, growing government support and increasing private investments and venture funding to support new product development are other factors that are propelling the growth of the market. In addition, rising adoption of POC devices, expansion of therapeutic horizon, and technological advancements is further fueling the growth of this market. However, a few pivotal factors such as lack of alignment with definitive central lab methods, and reluctance to change existing treatment practices are hindering the growth of this market. Moreover, disadvantages of POC testing over central lab methods and recalls of leading glucose monitoring devices are the foremost challenges faced by industry players. New product launches is the key strategy followed by leading market players to ensure their growth in the POC diagnostics market. Moreover, partnerships, agreements, collaboration, and joint ventures; mergers and acquisitions; and expansions are some other growth strategies adopted by industry players in the global market. Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Trends - Point-Of-Care Diagnostics Market, By Product - Point-Of-Care Diagnostics Market, By Prescription Mode - Point-Of-Care Diagnostics Market, By End User - Point-Of-Care Diagnostics Market, By Geography - Competitive Landscape - Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare Visit http://www.researchandmarkets.com/research/cd...ointofcare
CLIA Waiver for Abaxis' Lipid Profile Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 2:20PM CDT
Abaxis received the CLIA waiver status for capillary draw for cholesterol, high density cholesterol and triglycerides.
Abaxis Receives CLIA Waiver For Capillary Sampling For Cholesterol, HDL And Triglycerides
PR Newswire - Fri Mar 28, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced the Food and Drug Administration granted CLIA waived status for capillary draw for CHOL, HDL and TRIG. Combined with existing CLIA waived tests for liver diagnostics using capillary samples, Abaxis now has two complete Lipid Panels which can be used by healthcare professionals to diagnose, treat and monitor hyperlipidemia patients using a sample obtained from either venous blood or a capillary draw.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
